iSonea, a medical technology company with offices in USA and Australia , has announced that it has been awarded the US Patent 2009/0216127 A1 by the United States Patent and Trademark Office for its advanced cough count technology. The company develops non-invasive acoustic respiratory monitoring devices and mobile health apps.
Leveraging the iSonea’sFDA-approved Acoustic Respiratory Monitoring (ARM) technology, the ultrasound-based cough detector automatically counts coughing events by detecting the low and high frequency mechanical vibrations occurring in the patient’s tracheal area. The sensors in the device detects and records coughing events, tracks the duration and severity of each cough, and also wirelessly communicates the data to a log or to a computer.
The severity and distribution of cough needs to be accurately assessed for the diagnosis and treatment of cystic fibrosis, chronic obstructive pulmonary disease, asthma and gastroesophageal reflux disease.
The Chief Executive Officer of iSonea, Michael Thomas stated that the patent for cough detection expands the company’s patent portfolio. The technology will aid clinicians quantify cough to provide accurate diagnosis and better treatment for several respiratory conditions and diseases.
iSonea currently holds over 15 patents including patent no US 2006/0037615 A1 and US 7,347,824 B2 for the method and apparatus for determining conditions of biological tissues, patent no US 6,168,568 B1 and US 6,261,238 B1 for the Phonopneumograph System and patent no US 6,375,623 B1 for determination of apnea type.
The US FDA, the European Union CE and the Australian TGA have certified the ARM devices developed by iSonea.